Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T20:46:59.429Z.
Calculation as of: 2026-10-06T20:46:59.429Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8c49465b29cefd47847e7fc901c6d20b09f101de13d3ea96f762810498d8f388
PE RATIO
N/A
Market Cap
$49.25M
PE Ratio
N/A
TTM Avg
43.98
3Y Avg
82.17
5Y Avg
82.17
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| INmune Bio, Inc. (INMB) | $49.71M | N/A | N/A | N/A | N/A |
| Clene Inc. (CLNN)vs › | $49.45M | N/A | 13.56 | 13.56 | 13.56 |
| Precision Optics Corporation, Inc. (POCI)vs › | $49.25M | N/A | 43.98 | 82.17 | 82.17 |
| Envoy Medical, Inc. (COCH)vs › | $50.27M | N/A | 135.17 | 135.17 | 135.17 |
| biote Corp. (BTMD)vs › | $50.28M | 9.77 | 4.82 | 27.98 | 18.54 |
| Sensus Healthcare, Inc. (SRTS)vs › | $48.89M | N/A | 20.76 | 21.54 | 20.97 |
| TELA Bio, Inc. (TELA)vs › | $48.77M | N/A | N/A | N/A | N/A |
| Microbot Medical Inc. (MBOT)vs › | $48.76M | N/A | 6.87 | 6.87 | 6.87 |
| Apollomics, Inc. (APLM)vs › | $48.53M | N/A | N/A | N/A | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.12M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.87
Forward EPS (Est.)
$-0.55
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
